巨噬细胞集落刺激因子与不稳定型心绞痛患者预后的关系

目的 :评价巨噬细胞集落刺激因子 (MCSF)预测不稳定型心绞痛 (UAP)患者预后的价值。方法 :118例接受了冠状动脉造影或有心肌梗死史的BrauwaldⅢB型UAP患者纳入本研究。检测入选者血清MCSF、白细胞介素 6 (IL 6 )、C 反应蛋白 (CRP) ,并对其进行了 6个月的随访 ,按随访期间有无主要心脏事件发生分成两组 :Ⅰ组 :发生心脏事件 (n =6 8) ;Ⅱ组 :未发生心脏事件 (n =5 0 )。结果 :Ⅰ组患者血清MCSF、IL 6、CRP均显著高于Ⅱ组患者 [MCSF :(4 5 7.19± 6 6 .16 )∶(311.14± 4 8.2 2 )ng/L ;IL 6 :(8.6 8± 4 .6 1)∶(4 .5 9± 1.71)ng/L ;CRP :(8.6 9± 3.73)∶(3.34± 2 .0 8)mg/L ;三者均P <0 .0 1]。血清MCSF含量与IL 6 (r =0 .5 2 1,P <0 .0 1)和CRP(r =0 .5 2 8,P <0 .0 1)含量均呈显著正相关。多因素回归分析显示 ,血清MCSF水平是UAP随访期间发生心脏事件独立的、最强烈的预测因子 (P <0 .0 1)。结论 :UAP患者血清MCSF浓度增高时 ,可以预测其长期的不良心脏事件的发生     

老年心绞痛患者血浆醛固酮变化的研究

目的探讨老年患者醛固酮水平与心绞痛发生及预后的关系。方法测定老年心绞痛患者〔不稳定性心绞痛(UAP)及稳定性心绞痛〕血清醛固酮、肾素及血管紧张素水平,结果UAP组醛固酮水平明显高于健康对照组及稳定性心绞痛组(P<0001),稳定性心绞痛组高于健康对照组(P<005)。醛固酮>4398pmol/L时心脏事件的发生率明显高于小于此值者(P<0001)。结论老年心绞痛患者血清醛固酮水平与心绞痛严重程度及预后密切相关。     

C反应蛋白对不稳定型心绞痛患者预后的评价作用

目的探讨血清C反应蛋白(CRP)水平对不稳定型心绞痛(UAP)患者预后的评价作用。方法观察UAP58例,稳定型心绞痛69例作为对照组,两组均在住院后24h内采集静脉血,测血清CRP水平,出院后随访6个月,两组进行对比分析。结果UAP组CRP明显高于对照组,且UAP组在随访过程中发生急性心肌梗死(AMI)、心脏性死亡及其它心脏事件者CRP均高于对照组。除心脏性死亡外,均有统计学差异。结论CRP在UAP患者中均有不同程度增高,且发生AMI、心脏性死亡及其它心脏事件者的CRP更进一步增高。提示CRP对UAP患者的预后有一定的预测价值。     

心绞痛患者血浆醛固酮浓度变化的研究

目的:探讨醛固酮水平与心绞痛发生及预后的关系。方法:测定不稳定性心绞痛(UAP)及稳定性心绞痛 (SAP)患者血清醛固酮、肾素及血管紧张素水平,相互进行比较,并与健康对照组进行比较。结果:UAP组醛固酮水平明显高于健康对照组及SAP组(P<0．001),SAP组的又高于健康对照组(P<0．05)。醛固酮>427．4 pmol／ L时心脏事件的发生率(37．5％)明显高于≤427．4 pmol／L者(15．79％),P<0．01。结论:血清醛固酮水平可反映心绞痛严重程度,并有预后价值。     

C-反应蛋白是急性冠脉综合征的一种危险因子

目的　研究急性冠脉综合征 (包括不稳定性心绞痛、急性心肌梗死和心源性猝死 )患者血清C 反应蛋白(CRP)浓度水平并与对照组 (即非急性冠脉综合征 ,包括稳定性心绞痛、陈旧性心肌梗死和正常体检人群 )比较 ,探讨CRP是否为急性冠脉综合征的一种危险因子。方法　用速率散射比浊法测定急性冠脉综合征患者和对照组血清CRP浓度 ,同时检测冠心病的常见危险因子并与CRP一起作Lo gistic回归分析。结果　①急性冠脉综合征患者血清CRP浓度 [18 5 0mg/L± 2 3 98mg/L (SE 2 5 1,n =91) ]显著高于对照组 [3 89mg/L± 7 14mg/L (SE 0 5 1,n =194 ) ](P <0 0 1)。②急性心肌梗死急性期患者CRP浓度 (18 6 5mg/L± 2 4 12mg/L)和不稳定性心绞痛CRP浓度 (17 95mg/L±2 4 10mg/L)显著高于正常对照组 (P <0 0 1)、稳定性心绞痛CRP浓度 (3 94± 7 5 0mg/L) (P <0 0 1)、急性心肌梗死患者恢复期 (5 93mg/L± 13 0 7mg/L) (P <0 0 1)和陈旧性心肌梗死患者 (4 5 7mg/L± 8 2 7mg/L) (P <0 0 1) ;稳定性心绞痛患者、急性心肌梗死患者恢复期和陈旧性心肌梗死患者之间CRP浓度无差别 (P >0 0 5 )并与正常人群比较无显著性差别 (P >0 0 5 )。③每增加CRP 5mg/L ,急性冠脉综合征发生危险增加到近 2倍 (用Logistic回归 ,OR     

血清C反应蛋白对冠状动脉临界病变患者的临床预后价值

目的探讨血清C反应蛋白(CRP)对冠状动脉临界病变患者临床预后的价值。方法选择117例经冠状动脉造影提示临界病变的患者,测定其血清CRP,并按CRP水平分为高CRP组(CRP≥3mg/L)39例,正常CRP组(CRP<3mg/L)78例,比较1年内心性事件(包括顽固性心绞痛而行介入治疗、非致死性心肌梗死和心性死亡)的发生率。结果117例患者中高CRP组心性事件发生率明显高于正常CRP组(25.6%和2.6%,P<0.01),应用高CRP预测上述心脏事件的阴性和阳性预测值分别为97.4%和25.6%。结论血清CRP水平能预测冠状动脉临界病变患者1年间心性事件,可作为其危险分层的血清学指标。     

血清C-反应蛋白对不稳定型心绞痛患者预后的预测价值

目的　探讨不稳定型心绞痛(UAP)患者血清C -反应蛋白(CRP)水平与心血管事件发生的关系。方法　将UAP患者按入院2 4小时内血清CRP水平分为两组:低CRP组(CRP <3 .5mg·L-1) 4 6例,高CRP组(CRP≥3. 5mg·L-1) 5 8例。两组患者入院后均予常规内科治疗,比较2周内及随访6个月时两组发生心血管事件的情况。结果　(1)低CRP组2周内发生心绞痛总数次15 8例次,平均3 .4 3次/人,与高CRP组总2 86例次,平均4 .93次/人比较有显著性差异(P <0 . 0 5 ) ;随访6个月时,低CRP组共发生心绞痛2 0 1例次,平均4 .37次/人,与高CRP组总76 3例次,平均13. 1次/人比较有显著性差异(P <0 . 0 1) ;(2 )低CRP组2周内及随访6个月时发生急性心肌梗死(AMI)例数(% )分别为6例(13 .0 % )及2例(4 .4 % )与高CRP组18例(31 .0 % )及13例(2 2. 4 % )比较有显著性差异(P <0 . 0 5 ) ;(3)低CRP组随访6个月时发生猝死1例(2 . 2 % )与高CRP组5例(8. 6 % )比较无显著性差异(P >0 . 0 5 )。结论　血清CRP水平对UAP患者近远期心血管事件的发生有很高的预测价值。     

肌钙蛋白Ⅰ对老年不稳定性心绞痛患者危险分层的判断价值

目的　探讨心脏肌钙蛋白I(cTnI)对老年不稳定性心绞痛 (UAP)患者危险分层的判断价值。　方法　对 6 8例老年UAP患者、17例稳定性心绞痛 (SAP)患者及 11例健康对照者分别进行血清cTnI测定 ,并观察住院 1个月内心脏事件发生情况。　结果　UAP组血清cTnI值为 (1 94± 0 6 3)μg/L ,明显高于SAP组的 (0 6 1± 0 11) μg/L及对照组的 (0 47± 0 0 8) μg/L(均为P <0 0 1)。UAP组内 ,随着Braunwald临床分级增高 ,Ⅰ～Ⅲ级血清cTnI值相应增高〔分别为 (1 35± 0 2 8)、(2 0 4± 0 31)及(3 17± 0 74) μg/L〕(P <0 0 5 )。对照组、SAP组及BraunwaldⅠ级UAP患者无 1例发生心脏事件 ;BraunwaldⅡ级 1例患者发生非致命性心肌梗死 ;BraunwaldⅢ级患者中 ,血清cTnI≥ 1 5 μg/L者心脏事件发生率为 42 1% ,高于血清cTnI <1 5 μg/L者的 13 3% (P <0 0 5 ) ,比数比 (OR) 3 15 ,95 %可信限为1 0 1～ 9 81。血清cTnI≥ 1 5 μg/L时判断心脏事件的阳性预测值为 42 1% ,阴性预测值为 86 7%。　结论　血清cTnI检测对老年UAP患者危险分层有较好的判断价值。     

CRP对急性心肌梗死患者近期预后的预测价值

测定58例急性心肌梗死(AMI)患者和32例稳定性心绞痛(SAP)患者血浆C反应蛋白(CRP)水平,并随访AMI患者住院期间及3个月的主要不良心脏事件(MACE)发生率.结果 AMI患者CRP水平为(32.51±11.4)mg/L,明显高于对照组的(16.32±1.40) mg/L;AMI患者住院期间MACE发生率为10.7%,3个月总的MACE发生率为19%;发生MACE患者的CRP水平为(42.16±10.2)mg/L,明显高于无MACE者的(24.69±6.46)mg/L.提示检测CRP水平有利于预测AMI患者的近期预后.     

血清C反应蛋白对冠状动脉支架置入术后心血管事件和再狭窄的预测价值

目的　探讨基础血清C反应蛋白 (CRP)水平对冠状动脉支架置入术后 6个月内心血管事件和再狭窄的预测价值。方法　术前测定 78例单支病变的冠状动脉支架置入术患者 [2 8例稳定性心绞痛 (SAP)和 5 0例急性冠脉综合征 (ACS) ]基础血清CRP水平。将患者分为CRP <3 0mg/L(31例 )和CRP≥ 3 0mg/L (4 7例 )两组 ,分析并记录患者术后 1周以及术后 6个月内心血管事件 (心绞痛、心肌梗死及死亡 )发生率及支架内再狭窄 (血管内直径狭窄率≥ 5 0 % )等情况。结果　基础血清CRP水平在ACS组比稳定心绞痛组高 [(7 8± 2 6 )比 (2 8± 0 4 )mg/L ,P <0 0 1];术后 1周内的心血管事件发生率在ACS组、CRP升高组比稳定心绞痛、CRP不高组明显升高 (8%比 3 6 % ,P <0 0 5 ) ;术后6个月的心血管事件及支架内再狭窄发生率亦是CRP高者远高于CRP低者 (2 1 5 %比 7 7% ,P <0 0 1;19 5 %比 7 7% ,P <0 0 1)。结论　基础血清CRP水平是单支冠状动脉病变支架置入术后 6个月内预后的预测指标 ,这提示术后 6个月内心血管事件发生率和支架内再狭窄是和支架置入术前炎症细胞活化程度密切相关。     

Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris

Elevated C-reactive protein (CRP) can identify patients with coronary artery disease who are prone to future acute events. We investigated whether elevated CRP is related to the activation of the terminal complement cascade in 66 patients with unstable angina pectoris (UAP), in 45 patients with stable angina pectoris, and in 42 controls. CRP, additional acute phase reactants, the terminal complement complex (sC5b-9), leukocytes, and troponin T were measured. In 47 patients with UAP the CRP values were regarded as elevated (>0.3 mg/dl). In patients with UAP and elevated CRP, the plasma levels of sC5b-9 were markedly higher than in patients with UAP and lower CRP (245 +/- 14 vs 188 +/- 19 ng/ml, p <0.02) and in patients with stable angina pectoris with slightly (0.4 +/- 0.1 mg/dl) increased CRP (sC5b-9 173 +/- 21 vs 130 +/- 7 ng/ml [controls; p <0.05]). A further acute phase reaction was present only in patients with UAP and elevated CRP already on admission (p <0.01). sC5b-9 was not related to troponin release. Thus, elevated CRP levels are associated with activation of the plaque destabilizating terminal complement system in patients with UAP during the acute phase reaction. This may explain the prognostic value of CRP in acute coronary syndromes (ACS).     

Fluctuating inflammatory markers in patients with stable ischemic heart disease

BACKGROUND: C-reactive protein (CRP), a marker of inflammation, is increasingly measured to stratify coronary artery disease risk and guide clinical management. However, little is known about how inflammatory markers fluctuate over time in patients with stable ischemic heart disease. METHODS: We examined serial serum CRP values in 159 patients with histories spanning the clinical spectrum of ischemic heart disease. Two to 8 CRP measurements were made at intervals varying from 15 days to 6 years. Successive interleukin (IL)-6 values were examined in 1 subgroup. Blood samples were always taken when patients were clinically stable, in the absence of any potentially confounding inflammatory condition. RESULTS: C-reactive protein values in individual patients fluctuated considerably when examined in the following ranges: less than 1 mg/L, 1 to 3 mg/L, and greater than 3 mg/L, proposed to indicate low, average, and high risk. Sixty-four patients (40.3%) changed risk category between the first and the second measurement. Within-patient variances of CRP and IL-6 levels were 1.79 mg/L (95% confidence interval, 1.60-2.00) and 2.69 pg/mL (95% confidence interval, 2.29-3.18), respectively. The variability of CRP was consistent over different times and across clinical groups, and independent of body mass index, smoking status, medication, and clinical events. CONCLUSIONS: Relatively important fluctuations in CRP levels in patients with stable ischemic heart disease may be problematic for risk stratification and treatment monitoring. A similar IL-6 variability suggests that these patients have a dynamic inflammatory status whose kinetics may modulate acute coronary risk.     

C-反应蛋白水平与冠脉支架术后心血管事件和再狭窄的相关性研究

目的探讨血清C反应蛋白(CRP)对支架术后6个月内心血管事件和1年内再狭窄的相关预测价值。方法对62例单支病变行冠状动脉支架植入术患者术后72小时测定血清CRP水平并记录患者术后3天至6个月来心血管事件(心绞痛、心肌梗死及死亡)及1年来支架内再狭窄情况。结果发生心血管事件组CRP水平明显高于未发生组(9.65±2.98mg/LVS7.53±2.76mg/L,P<0.05),CRP增高组与CRP正常组心血管事件发生率相似(18.0%VS8.3%P>0.05),血清CRP水平与冠脉支架术后6～12个月再狭窄无显著差异(7.58±2.16mg/LVS7.21±2.34mg/L,P>0.05;14.6%VS16.7%,P>0.05)。结论冠脉支架术后发生心血管事件与CPR水平明显相关,术后再狭窄与CPR水平无显著相关性。     

Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity

An increased serum interleukin-6 (IL-6) level is associated with an increased risk of cardiovascular events in healthy subjects. However, it is unknown whether the level of serum IL-6 or genetic IL-6 polymorphism is correlated with the complexity of coronary plaque in patients with stable coronary artery disease (CAD). Patients with stable CAD (n = 135) were divided into 3 groups: insignificant coronary plaque (n = 77), simple coronary plaque (n = 15), and complex coronary plaque (n = 43). IL-6-174G > C polymorphism and serum levels of IL-6 and C-reactive protein (CRP) were investigated. No significant difference in the distribution of IL-6 genotypes was found among the groups. The presence of complex coronary plaque was associated with higher serum concentrations of IL-6 (P = 0.026) and CRP (P < 0.0001). To predict the presence of complex lesions, IL-6 > 5.8 ng/L and CRP > 2.6 mg/L had sensitivities of 86% and 74%, and specificities of 61% and 62%, respectively. By multivariate analysis, IL-6 > 5.8 ng/L and CRP > 2.6 mg/L were independently related to the presence of complex coronary plaque (P = 0.0002 and 0.004, respectively). IL-6 > 5.8 ng/L and CRP > 2.6 mg/L were associated with a 4.5-fold increase in the odds of having complex coronary plaque (P < 0.005). A simple measurement of the serum IL-6 level in patients with CAD can potentially identify subjects with complex coronary lesions and provide the option of aggressive medical strategies in a clinical setting.     

Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease.

AIMS: We investigated, in a 6 year follow-up study, whether circulating levels of C-reactive protein (CRP) and macrophage colony stimulating factor (MCSF) have an independent or complementary prognostic value in patients with chronic coronary artery disease (CAD). METHODS AND RESULTS: MCSF and CRP were measured in 100 patients with chronic CAD. Of 95 (33%) patients, 31 who completed the 6 year follow-up presented adverse events (death, myocardial infarction, and unstable angina). In multivariable analysis (including traditional risk factors and medications), the upper tertiles of MCSF (> or =814 pg/mL) and CRP (> or =2.5 mg/L) levels were independently associated with a 13- and 6-fold increase in risk of events, respectively (P<0.01). Patients with combined high CRP and MCSF had a higher absolute risk of events than patients with elevated MCSF or CRP alone (75 vs. 59 vs. 32%, respectively, P<0.01). The mean event-free time was 39, 64, and 52 months in patients with elevated MCSF, elevated CRP, and their combination, respectively. CONCLUSION: In patients with chronic CAD, the prognostic value of MCSF is independent and complementary to that of CRP. MCSF is a particularly useful prognostic marker when CRP levels are low, but also provides additional information concerning risk and time-course of events in patients with elevated CRP.     

Inflammatory markers and elderly patients with stroke

C-reactive protein (CRP) is associated with unfavorable outcome in patients with acute ischemicsyndromes and in patients with chronic stable angina.Elevated CRP levels suggestive of heightened inflammatorystate in vascular conditions are often associated with elevated interleukin-6 (IL-6) levels.The aim of our study wasto show the predictive importance of CRP and IL-6 levels in patients with ischemic stroke that has not been fullyelucidated.Design We studied 647 consecutive elderly patients (>65 years) with stroke who were documentedwith ischemic stroke,presence of significant carotid atherosderosis and absence of atrial fibrillation.The studypopulation included 150 patients (74 men,76 women,mean age 74±2).Patients underwent evaluation of highsensitive CRP and IL-6 levels at baseline,during hospitalization and at discharge.Results In-hospital mortalitywas 6%,1 year mertality was 15% and a second cerebrovascular event occurred in 12% of patients.Those with in-hospital events had significantly higher baseline CRP and IL-6 levels than patients without events (3.8+1.1 vs1.9±0.9 mg/L,P<0.01 and 13.8±3.4 vs 6.3±2.1 pg/ml,P<0.01,respectively).Also CRP and IL-6levels were significantly higher in those patients with an event within 3 months of discharge compared to patientswithout an event (3.6±1.3 vs 1.1±0.7 mg/L,P<0.01 and 14.2±3.7 vs 5.4±1.6 pg/ml,P<001,respectively).Both base line CRP levels and IL-6 were predictive of events both in-hospital and after 3 months whileCRP and IL-6 levels at baseline were not associated with a poor 1 year prognosis.Elevated CRP levels wereassociated with an unfavorable outcome only when IL-6 levels were also elevated.In a stepwise multivariate analysisIL-6 level was a stronger predictor of outcome than CRP.Conclusions In conclusion,elevated CRP and IL-6levels may identify elderly patients at increased medium term risk,but do not predict one year events in this subsetof patients.CRP levels predict events only when they are coupled with IL-6 levels.(J Ceriatr Cardiol 2004;1:44-48.)     

C-反应蛋白、内皮功能变化与急性冠状动脉综合征相关性研究

目的　探讨 C-反应蛋白及肱动脉流量介导的血管舒张在急性冠状动脉综合征中的变化及其相关性。方法　急性冠状动脉综合征 (ACS)组 5 1例 ,其中急性心肌梗死 (AMI) 15例 ,不稳定性心绞痛 (U AP) 36例 ;选择 2 2例冠状动脉造影除外冠心病的患者为对照组。用速率散射比浊法测血清 C-反应蛋白 (CRP) ,用高分辨率超声测肱动脉反应性充血引起的流量介导血管扩张 (FMD)与硝酸甘油介导的血管扩张 (NTG)。结果　 ACS组 CRP高于对照组(0 .94± 1.45 mg/ dl vs0 .2 7± 0 .2 1mg/ dl,P<0 .0 5 ) ,AMI亚组 CRP明显高于 UAP亚组与对照组 (1.6 4± 1.82mg/ dl vs0 .6 5± 1.17m g/ dl、 0 .2 7± 0 .2 1m g/ dl,P<0 .0 5 ) ,UAP亚组高于对照组 (0 .6 5± 1.82 m g/ dl vs0 .2 7±0 .2 1m g/ dl,P>0 .0 5 )。ACS组的 FMD明显低于对照组 (4 .6 1± 2 .2 1mm vs9.2 3± 3.45 mm,P<0 .0 5 ) ,而 NTG与对照组比较则无差别。经 logisitic回归分析 ,CRP的风险比值 (OR)值大于 1,是 ACS的危险因素 ,FMD的 OR值小于 1,是 ACS的保护因素。经前进法观察 CRP与 FMD在急性冠脉综合征中的作用是相互独立的。结论　急性冠状动脉综合征患者 C-反应蛋白升高 ,内皮功能受损 ,二者是 ACS发生的独立危险因素     

高敏C-反应蛋白对经皮冠状动脉介入术后对比剂肾病风险预测价值

目的:探讨经皮冠状动脉介入治疗术前高敏C反应蛋白(hs-CRP)水平与患者术后对比剂急性肾损伤(CI-AKI)的发生率及远期预后的关系。方法:连续入选1 820例于我院行择期经皮冠状动脉介入治疗患者,排除急性心肌梗死、近期手术或创伤的患者。根据术前hs-CRP值分为3组:hs-CRP升高组(hs-CRP>3 mg/L,n=546)、hs-CRP轻度升高组(hs-CRP 1～3 mg/L,n=650)和hs-CRP正常组(hs-CRP<1 mg/L,n=624)。结果:中位随访时间为26个月。与hs-CRP正常组相比,hs-CRP升高组术后CI-AKI发生率显著增加(10.9%vs.14.8%vs.23.1%,P<0.0001)。经过Logistic回归校正临床基线资料后,术前hs-CRP水平仍然是对比剂急性肾损伤发生率的独立预测因素。此外,男性OR=0.61;95%CI=0.45～0.82;P=0.001),糖尿病(OR=2.21,95%CI=1.67～2.93;P<0.0001),围手术期水化治疗(OR=0.50,95%CI=0.38～0.65,P<0.0001)也是患者对比剂肾病风险的独立预测因素。结论:术前hs-CRP水平与经皮冠状动脉介入治疗术后CI-AKI发生率显著相关。hs-CRP水平可以为患者术前危险分层提供帮助。     

Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting.

AIMS: Inflammatory markers may serve as an important prognostic predictor in patients with coronary heart diseases. In patients undergoing coronary interventions, it has been shown that baseline C-reactive protein (CRP) could predict late clinical restenosis. Only a few small studies have examined the possible relationship with angiographic restenosis. In patients with stable angina pectoris,we examined whether baseline CRP and IL-6 predict late coronary angiographic restenosis after stenting. METHODS AND RESULTS: Pre-procedural plasma levels of CRP and IL-6 were measured in 216 patients with stable angina pectoris undergoing elective coronary stenting. Angiographic follow-up was performed in all patients at 6 months. Baseline CRP levels were 6.15 +/- 0.78 mg/L versus 5.24 +/- 1.17 mg/L in the patent and restenosis groups, respectively (P=0.64). IL-6 levels were 0.46 +/- 0.03 ng/L versus 0.40 +/- 0.07 ng/L in the patent and restenosis groups, respectively (P=0.50). CRP levels were obtained again at the time of angiographic follow-up and were found to be similar in both groups (2.89 +/- 0.29 mg/L versus 2.61 +/- 0.63 mg/L, P=0.72). Moreover, in a sub-group of 43 patients, serial blood samples were obtained at several time points after the procedure up to 6 months. Both CRP and IL-6 plasma levels increased significantly in response to the procedure. CRP levels peaked at 3 days (11.27 +/- 1.53 mg/L versus 4.26 +/- 0.72 mg/L at baseline, P<0.0001). IL-6 levels reached maximum values after 24 h (1.08 +/- 0.14 ng/L versus 0.53 +/- 0.08 ng/L at baseline, P<0.0001). However, in this sub-group of patients, neither peak CRP nor IL-6 levels were found to predict late angiographic restenosis. CONCLUSIONS: Coronary stenting is associated with transient increases in both CRP and IL-6 levels. However, pre-procedural CRP and IL-6 levels do not predict late coronary angiographic restenosis.